GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa.

GSK plc and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious liver diseases, announced that they have entered ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston ...

Bayer and GSK have a Zacks Rank #2 (Buy) each, while Novo Nordisk, AbbVie, and Merck carry a Zacks Rank of 3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

GSK is paying $1.2 billion upfront to Boston Pharmaceuticals for an experimental drug to treat MASH. Eli Lilly plans to expand Purdue University collaboration with up to a $250 million investment ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston Pharmaceuticals, pledging another $800 million in milestone payments if the ...

Wall Street major averages closed significantly higher on Friday, despite softer-than-expected inflation data, and consumer sentiment dropping to the second-lowest on record. Week-to-date, the U.S.

GSK Buys Rights to Phase III-Ready Liver Disease Candidate GSK announced that it is buying rights to clinical-stage biotech Boston Pharmaceuticals’ lead pipeline candidate, efimosfermin alfa ...

currently with Boston Pharmaceuticals and Pfizer, which also involve 4-1BB bispecific proteins. Pfizer is developing SGN-BB228, a CD228/4-1BB candidate it inherited as part of its takeover of ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Torrent Pharmaceuticals is entering a new chapter as Aman Mehta, next-gen scion of the Mehta family, prepares to take over as ...